WXFL-10203614

N/A

Report date: 2025/11/25 15:52:29
NME

Base Information

Drug NameWXFL-10203614
Drug Alias NameWXFL-10203614
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK1 inhibitors
TargetsTyrosine-protein kinase JAK1
Therapy Area/IndicationsDermatitis, AtopicCrohn DiseaseColitis, Ulcerative +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesWuxi Fuxin Pharmaceutical Research And Development Co LtdWuxi Apptec Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesWuxi Fortune Pharmaceutical Co LtdWuxi Fuxin Pharmaceutical Research And Development Co Ltd
Inactive CompaniesN/A
Active IndicationsDermatitis, AtopicCrohn DiseaseColitis, Ulcerative +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A